Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura

被引:348
作者
Zheng, XL
Kaufman, RM
Goodnough, LT
Sadler, JE
机构
[1] Barnes Jewish Hosp, Dept Pathol & Immunol, St Louis, MO 63110 USA
[2] Barnes Jewish Hosp, Dept Med, St Louis, MO 63110 USA
[3] Washington Univ, Sch Med, Howard Hughes Med Inst, St Louis, MO USA
[4] Univ Penn, Childrens Hosp Philadelphia, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA
关键词
D O I
10.1182/blood-2003-11-4035
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Therapeutic plasma exchange is an effective empiric treatment for thrombotic thrombocytopenic purpura (TTP), but how therapy affects the level of a disintegrin and metalloprotease with thrombospondin type 1 motif 13 (ADAMTS13) or inhibitor has not been reported in many patients. We prospectively analyzed ADAMTS13 activity and inhibitor levels in 37 adults with TTR ADAMTS13 level at presentation was lower than 5% in 16 of 20 patients with idiopathic TTP and in none of 17 patients with TTIP associated with hematopoietic stem cell transplantation, cancer, drugs, or pregnancy (P < .00001). Seven of the 16 patients with ADAMTS13 activity lower than 5% (approximate to 44%) had inhibitors. For 8 patients followed serially with ADAMTS13 activity lower than 5% but no inhibitor at presentation, plasma exchange led to complete clinical remission and a rise in ADAMTS13 level. In contrast, 4 patients with low ADAMTS13 activity but high-titer inhibitor (> 5 units/mL) had neither a rise in ADAMTS13 activity nor a reduction in the inhibitor titer: 3 had recurrent disease and 1 died. Among 17 patients with ADAMTS13 activity at presentation higher than 25%, 10 died. Mortality rate for idiopathic TTP was 15%, whereas mortality for nonidiopathic TTP was 59% (P < .02). We conclude that assays of ADAMTS13 activity and inhibitors in addition to the clinical categories (idiopathic TTP and nonidlopathic TTP) are predictive of outcome and may be useful to tailor patient treatment. (C) 2004 by The American Society of Hematology
引用
收藏
页码:4043 / 4049
页数:7
相关论文
共 51 条
[1]   Thrombotic thrombocytopenic purpura following stem cell transplantation [J].
Allford, SL ;
Bird, JM ;
Marks, DI .
LEUKEMIA & LYMPHOMA, 2002, 43 (10) :1921-1926
[2]   THROMBOTIC THROMBOCYTOPENIC PURPURA - REPORT OF 16 CASES AND REVIEW OF LITERATURE [J].
AMOROSI, EL ;
ULTMANN, JE .
MEDICINE, 1966, 45 (02) :139-+
[3]   ADAMTS13 gene defects in two brothers with constitutional thrombotic thrombocytopenic purpura and normalization of von Willebrand factor-cleaving protease activity by recombinant human ADAMTS13 [J].
Antoine, G ;
Zimmermann, K ;
Plaimauer, B ;
Grillowitzer, M ;
Studt, JD ;
Lämmle, B ;
Scheiflinger, F .
BRITISH JOURNAL OF HAEMATOLOGY, 2003, 120 (05) :821-824
[4]   Mutation analysis and clinical implications of von Willebrand factor-cleaving protease deficiency [J].
Assink, K ;
Schiphorst, R ;
Allford, S ;
Karpman, D ;
Etzioni, A ;
Brichard, B ;
van de Kar, N ;
Monnens, L ;
van den Heuvel, L .
KIDNEY INTERNATIONAL, 2003, 63 (06) :1995-1999
[5]   IMPROVED SURVIVAL IN THROMBOTIC THROMBOCYTOPENIC PURPURA HEMOLYTIC UREMIC SYNDROME - CLINICAL-EXPERIENCE IN 108 PATIENTS [J].
BELL, WR ;
BRAINE, HG ;
NESS, PM ;
KICKLER, TS .
NEW ENGLAND JOURNAL OF MEDICINE, 1991, 325 (06) :398-403
[6]   VWF meets the ADAMTS family [J].
Brass, L .
NATURE MEDICINE, 2001, 7 (11) :1177-1178
[7]   Transplantation-associated thrombotic microangiopathy: twenty-two years later [J].
Daly, AS ;
Xenocostas, A ;
Lipton, JH .
BONE MARROW TRANSPLANTATION, 2002, 30 (11) :709-715
[8]  
Elkins SL, 1996, J CLIN APHERESIS, V11, P173
[9]   Posttransplantation thrombotic thrombocytopenic purpura: A single-center experience and a contemporary review [J].
Elliott, MA ;
Nichols, WL ;
Plumhoff, EA ;
Ansell, SM ;
Dispenzieri, A ;
Gastineau, DA ;
Gertz, MA ;
Inwards, DJ ;
Lacy, MQ ;
Micallef, INM ;
Tefferi, A ;
Litzow, MR .
MAYO CLINIC PROCEEDINGS, 2003, 78 (04) :421-430
[10]   The clinical features, risk factors and outcome of thrombotic thrombocytopenic purpura occurring after bone marrow transplantation [J].
Fuge, R ;
Bird, J M ;
Fraser, A ;
Hart, D ;
Hunt, L ;
Cornish, JM ;
Goulden, N ;
Oakhill, A ;
Pamphilon, DH ;
Steward, CG ;
Marks, DI .
BRITISH JOURNAL OF HAEMATOLOGY, 2001, 113 (01) :58-64